Literature DB >> 15172628

New trends in specific immunoadsorption.

Heidrun Ullrich1, Peter Kuehnl.   

Abstract

Plasma exchange is widely accepted to remove pathogenic substances from patients' blood that cannot be eliminated otherwise like cholesterol in severe forms of familial hypercholesterolaemia or immunoglobulins and circulating immune complexes (CIC) in many autoimmune disorders. But dilution of other plasma proteins, as well as side effects and costs of substitution fluids, limit its efficiency. In immunoadsorption, the pathogen is bound specifically, generally no substitution fluids are needed and plasma can be conducted over the immunoadsorption columns as often as needed to achieve any reduction that one aims at, in some instances below the detection limit (e.g. HLA-antibodies in transplantations). The frequency of aphaereses is determined by the speed of the patients' improvement and the rebound of the eliminated substance, which can in some disorders be slowed down or stopped by concomitant immunosuppression. Generally, immunoadsorption is used in patients, where less expensive and demanding treatment options have failed, like severe hypercholesterolaemia, autoimmune disorders or hyperviscosity syndromes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172628     DOI: 10.1016/j.transci.2004.01.007

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  2 in total

1.  Immunoadsorption of alloantibodies onto erythroid membrane antigens encapsulated into polymeric microparticles.

Authors:  Valérie Hoffart; Philippe Maincent; Alf Lamprecht; Véronique Latger-Cannard; Véronique Regnault; Christian Merle; Valérie Jouan-Hureaux; Thomas Lecompte; Claude Vigneron; Nathalie Ubrich
Journal:  Pharm Res       Date:  2007-06-14       Impact factor: 4.200

2.  Immunoadsorption therapy in autoimmune encephalitides.

Authors:  Müjgan Dogan Onugoren; Kristin S Golombeck; Corinna Bien; Mariam Abu-Tair; Marcus Brand; Michael Bulla-Hellwig; Hubertus Lohmann; Dieter Münstermann; Hermann Pavenstädt; Gerold Thölking; Rainer Valentin; Heinz Wiendl; Nico Melzer; Christian G Bien
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.